Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations

Background-The aim of this study was to test the hypothesis that the chroni c inflammatory process present in chronic obstructive pulmonary disease (CO PD) is due to a defective endogenous antiinflammatory mechanism. Methods-Systemic levels of the antiinflammatory mediators soluble interleuk in 1 receptor II (sIL-1RII), soluble tumour necrosis factor receptor p55 (s TNF-R55) and sTNF-R75, and of C reactive protein (CRP) and lipopolysacchari de binding protein (CRP) were analysed in 55 patients with stable COPD (med ian forced expiratory volume in one second (FEV1) 34%6 predicted (range 15- 78)) and compared with levels in 23 control subjects. In addition, changes in these mediators were studied in 13 patients with COPD (median FEV1 34% p redicted (range 19-51)) during the first 7 days in hospital with an exacerb ation of the disease. Results-Patients with stable COPD were characterised by a systemic inflamma tory process indicated by an increased leucocyte count (7.2 (4.7-16.4) nu 4 .8 (3.5-8.3) x 10(9)/1), raised levels of CRP (11.8 (1.1-75.0) nu 4.1 (0.6- 75.0) mug/ml) and LBP (45.6 (8.1-200.0) nu 27.9 (14.1-71.5) mug/ml), and mo derate increases in both sTNF-Rs. In contrast, the sIL-1RII level did not d iffer between patients and controls (4.53 (2.09-7.60) nu 4.63 (3.80-5.93) n g/ml). During treatment of disease exacerbations, systemic levels of both C RP (at day 3) and LBP (at day 7) were significantly reduced compared with d ay 1, whereas sIL-1RII levels increased. Conclusions-These data suggest an imbalance in systemic levels of pro- and anti-inflammatory mediators in patients with stable COPD. The increase in t he and-inflammatory mediator sIL-1RII during treatment of exacerbations may contribute to the clinical improvement.